SCHEMBL6454364

SCHEMBL6454364

Oc1cc(OCc2ccccc2)ccc1-c1nc(-c2ncccn2)n[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
NPSR1 Q6W5P4 4/20 0.51
MAPK1 P28482 4/20 0.51
KDM4E B2RXH2 3/20 0.51
HSP90AA1 P07900 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
CYP3A4 P08684 1/20 0.47
NOD2 Q9HC29 1/20 0.47
ADORA2A P29274 1/20 0.46
ALOX5 P09917 1/20 0.44
MAOB P27338 5/20 0.44
MAOA P21397 3/20 0.44
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
PTGS1 P23219 1/20 0.43
SLC6A2 P23975 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTGS2 P35354 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6461029 0.90 SMN1; SMN2 (0.52) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6452129 0.86 MAPT (0.45) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6450788 0.86 MAPT (0.45) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6448806 0.84 MAPT (0.48) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6457001 0.83 MAPT (0.45) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6450113 0.83 MAPT (0.43) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL7048002 0.83 SMN1; SMN2 (0.50) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6452049 0.82 IDH1 (0.56) MAPTNPSR1MAPK1ADORA2ALMNA
SCHEMBL6449741 0.82 MAPT (0.46) MAPTNPSR1MAPK1KDM4EHSP90AA1
SCHEMBL6451157 0.80 MAPT (0.44) MAPTNPSR1MAPK1KDM4EHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC MAPT 2805/4885NPSR1 3086/4885MAPK1 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.